Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more.

Choose a location

    Excipients for Drug Formulation Crystallization Inhibition

    Crystallization inhibition for enhanced bioavailability – BASF functional solutions for solid and liquid formulations

    Crystallization inhibition is an important factor to maintain drug solubility and bioavailability out of solid and liquid dosage forms in particular. BASF offers a range of well established crystallization inhibitors that ensure that your drug will not get lost on its way to the point of action in the body.

    Inhibiting crystallization can be critical to maintain a certain solubilization of a drug within a medium. Because bioavailability of the crystalline form of an active ingredient is typically significantly lower in comparison to the dissolved state. Crystallization can be inhibited both in liquid and in solid formulations. Potential recrystallization in a liquid form can take place at any point in time after formulation, during storage or administration. In solid dosage forms, an active ingredients is less prone to recrystallization over the period of its storage, even though it can still takes place.

    Crystallization inhibition for liquid and solid formulations
    Trusted functional performance
    Comprehensive range of crystallization inhibitors of different molecular weight
    Pyrogen free Kollidon® 12 PF & Kollidon® 17 PF for parenteral formulations

    Yet the critical moment comes when the drug is administered and the dosage form dissolved in the gastric tract – the drug is then exposed to gastric liquids. Before it can be adsorbed, recrystallization can happen, causing bioavailability to plummet and a consequent loss of medication efficacy.

    BASF povidones like Kollidon® 17 PF and copovidones like Kollidon® VA 64 are proven crystallization inhibitors for liquid dosage forms, and we are working with our customers to find the effective solutions for crystallization inhibition in solid forms.

    Discover more about our crystallization inhibition solutions

    Product One Pager

    Kollidon® 12 PF / Kollidon® 17 PF - The endotoxin-controlled PVP-based solubilizers for parenteral and oral dosage forms

    Application Guide

    Solubility Enhancement with BASF Pharma Polymers - Solubilizer Compendium


    The Science of Insolubility Experts come together to discuss the chemistry of solubility – and the solutions of the future


    The Formulation Complex Unravelling the challenges and trends in formulation best practice – and why lipids and softgels are leading the way.


    Current Solubilization Techniques: Insights from the BASF Solubilization Symposium

    Application Guide

    Kollidon® Polyvinylpyrrolidone excipients for the pharmaceutical industry

    Portfolio Overview

    Focusing on your needs with platform solutions

    Download Center

    Looking for application guides, technical and scientific posters, brochures or technical information? Visit our Download Center.